A Retrospective Chart Study Evaluating the Role of Small Cystic Macular Changes as a Prognostic Factor for the Recurrence of Macular Oedema (ME) in Patients Treated with Ranibizumab (IVR) or Bevacizumab (IVB) for Macular Oedema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO)

Trial Profile

A Retrospective Chart Study Evaluating the Role of Small Cystic Macular Changes as a Prognostic Factor for the Recurrence of Macular Oedema (ME) in Patients Treated with Ranibizumab (IVR) or Bevacizumab (IVB) for Macular Oedema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top